KR20020031911A - crude drug for 2type diabetes - Google Patents

crude drug for 2type diabetes Download PDF

Info

Publication number
KR20020031911A
KR20020031911A KR1020000062697A KR20000062697A KR20020031911A KR 20020031911 A KR20020031911 A KR 20020031911A KR 1020000062697 A KR1020000062697 A KR 1020000062697A KR 20000062697 A KR20000062697 A KR 20000062697A KR 20020031911 A KR20020031911 A KR 20020031911A
Authority
KR
South Korea
Prior art keywords
weight
extract
diabetes
cordyceps sinensis
red ginseng
Prior art date
Application number
KR1020000062697A
Other languages
Korean (ko)
Other versions
KR100376030B1 (en
Inventor
고성권
Original Assignee
김재수
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김재수 filed Critical 김재수
Priority to KR10-2000-0062697A priority Critical patent/KR100376030B1/en
Publication of KR20020031911A publication Critical patent/KR20020031911A/en
Application granted granted Critical
Publication of KR100376030B1 publication Critical patent/KR100376030B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/066Clavicipitaceae
    • A61K36/068Cordyceps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254Acanthopanax or Eleutherococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: A crude drug formulation containing an extract of Ginseng radix rubra, Acanthopanax Senticosus and Cordyceps sinensis as a main component is provided which has significantly increased efficacy in treating a human suffering from the Syndrome of Type 2 Diabetes. CONSTITUTION: This crude drug formulation contains 60.4% by weight of a Ginseng radix rubra extract, 23.1% by weight of an Acanthopanax Senticosus extract, 4.6% by weight of a Cordyceps sinensis extract and multi-vitamins(0.046% by weight of B1, 0.046% by weight of B2, 0.046% by weight of B6, 0.002% by weight of B12, 2.3% by weight of C and 0.46% by weight of E).

Description

2형 당뇨에 효능이 있는 생약제제{crude drug for 2type diabetes}Crude drug for 2type diabetes

본 발명은 2형 당뇨에 효능이 있는 생약제제로 보다 상세하게는 홍삼, 가시오가피, 동충하초의 추출물과 멀티-비타민을 주원료로 한 2형 당뇨 치료에 효능이 있는 생약제제에 관한 것이다.The present invention relates to a herbal drug that is effective for type 2 diabetes, and more particularly, to an herbal drug that is effective for treating type 2 diabetes, which is mainly composed of extracts of red ginseng, barberry, cordyceps and multi-vitamin.

본 발명에서 이용되는 가시오가피는 오가피속에 포함되는 식물 중 하나를 의미하는 것이나, 이하 실시예 등의 중복을 피하기 위하여 가시오가피종만을 대표적으로 언급한다.Prickly Ogapi used in the present invention means one of the plants included in the genus Ogapi, to avoid the duplication of the following examples and the like only representatively refers to prickly Ogapi species.

본 발명은 홍삼, 가시오가피, 동충하초의 잎·줄기 또는 뿌리의 추출물과 멀티-비타민을 주원료로 하고 홍삼, 가시오가피, 동충하초 추출물의 배합비를 달리하여 실험한 결과 2형 당뇨 실험동물인 KKAY마우스에 1달간 경구투여하여 공복시 혈당치를 측정한바 혈당량이 현저하게 감소됨으로써 2형 당뇨병을 치료하는 생약제제를 발명하게된것이다.In the present invention, the extracts of the leaves, stems or roots of red ginseng, spiny gingival and Cordyceps sinensis and multi-vitamin were used as the main ingredients, and the mixing ratios of the extracts of the red ginseng, spiny ginseng and Cordyceps sinensis were tested for 1 month in KKA Y mice, a type 2 diabetic experimental animal. As a result of oral administration of fasting blood glucose levels, blood glucose levels were markedly reduced, leading to the invention of herbal preparations to treat type 2 diabetes.

상기 KKAY마우스란 생물공학적으로 조작하여 유전적으로 2형 당뇨에 걸려있는 실험용 마우스를 말한다. The KKA Y mouse refers to a laboratory mouse genetically manipulated to type 2 diabetes.

당뇨병이란 불연소된 당이 소변으로 배설되는 병으로 의학적으로는 혈중의 당의 농도가 높은 경우에 당뇨병이라고 진단한다. 건강한 사람의 정상적인 혈당수치는 혈액 1데시리터당 80∼120 ㎎으로 이 수치이상의 고혈당 상태가 지속되면 혈액순환이 나빠지고 세포의 손상이 가해지는데, 당뇨에 의한 고혈당은 당의 대사에 관여하는 호르몬인 인슐린이 부족하거나 전혀 생산되지 않는 경우를 1형 당뇨라고 하고, 인슐린이 제대로 분비되어도 불활성화되어 당을 에너지로 바꾸는데 활용되지 못한 경우를 2형 당뇨라고 하는데, 우리 나라 당뇨환자의 90 %가 2형 당뇨의 환자이다.Diabetes is a disease in which unburned sugars are excreted in the urine and medically diagnosed as diabetes when the blood sugar level is high. Normal blood glucose levels in healthy people are 80-120 mg per 1 deciliter of blood. If hyperglycemia above this level persists, blood circulation worsens and cell damage is incurred. Insufficient or not produced at all is called type 1 diabetes, and when insulin is properly secreted, it is inactivated and not used to convert sugar into energy. Type 2 diabetes is known. Patient.

즉, 인슐린이 체내의 혈당량을 조절하는데 있어서, 인슐린의 작용이 정상이면 흡수된 당이 다소 많아도 그 체내 이용을 촉진함으로써 혈당량을 정상적으로 유지할 수 있지만, 인슐린이 활발하지 못한 상태에서는 세포내의 당의 흡수가 정상적으로 이루어지지 못하므로 혈액속의 당이 증가하게 되는 것이다.In other words, when insulin regulates the blood glucose level in the body, if the action of insulin is normal, even though the absorbed sugar is somewhat higher, the blood glucose level can be maintained by promoting the use of the body, but in the state where the insulin is not active, the absorption of the sugar in the cell is normal. Because it is not made, the sugar in the blood will increase.

이와 같은 당뇨병을 치료하기 위하여는 음식섭취로 조절하는 식이요법 및 규칙적이고 적당한 운동을 하는 운동요법을 병행하여 인슐린분비를 촉진하거나, 분비된 인슐린이 정상적으로 작용할 수 있도록 의약품을 복용하거나 인슐린 주사를 맞는 것이 일반적인 치료방법이었다.In order to treat this type of diabetes, a diet controlled by food intake and exercise exercises with regular and moderate exercise may promote insulin secretion, or may take medicine or inject insulin to allow the insulin to function normally. It was a common treatment.

지금까지의 당뇨실험의 경우 사용한 실험동물에 화학물질(STZ, alloxan 등)을투여하여 췌장베타세포에 손상을 입혀 얻은 형태로, 이들은 화학물질을 투여한 용량에 따라 차이가 있기는 하지만 대다수 베타세포의 상당부분이 파괴되어 인슐린 분비능이 거의 없는 제1형 당뇨모델에 가깝다고 할 수 있고 또한 사람의 당뇨병과는 상당한 거리가 있는 모델이었다. 따라서 이러한 질환모델을 이용하여 시료들의 약효를 검색하는 것에는 상당한 오류가 예상되었다.Until now, diabetic experiments have been performed by injecting chemicals (STZ, alloxan, etc.) into the experimental animals used to damage pancreatic beta cells, which are largely dependent on the dose to which the chemicals are administered. It was a model that had been destroyed much of the close to the type 1 diabetes model with little insulin secretion ability, and also a considerable distance from human diabetes. Therefore, a significant error was expected to search for the efficacy of the samples using this disease model.

본 발명에서는 이제까지의 혈당강하 실험의 문제점들을 보완하여 궁극적으로 인슐린저항성을 개선시킴으로써 혈당강하 효능이 뚜렷한 새로운 2형 항당뇨 생약제제를 제공하고자 하는 것이다.The present invention is to provide a new type 2 antidiabetic herbal drug with a clear hypoglycemic effect by supplementing the problems of the hypoglycemic experiment so far and ultimately improving insulin resistance.

본 발명은 2형 당뇨에 효능이 있는 생약제제에 관한 것으로서, 홍삼, 가시오가피, 동충하초의 잎·줄기 또는 뿌리의 추출물과 멀티-비타민을 주원료로 하고 홍삼, 가시오가피, 동충하초 추출물의 배합비를 달리하여 제조한 생약제제이다.The present invention relates to a herbal preparation that is effective in type 2 diabetes, and prepared by varying the ratio of the extracts of red ginseng, spiny ginseng, leaf, stem or root of Cordyceps sinensis and multi-vitamins, and the red ginseng, spiny ginseng, Cordyceps sinensis extract. It is a herbal medicine.

홍삼(Ginseng Radix rubra)은 인삼(Panax ginseng)을 껍질채 쩌서 말린것으로 주로 폐(肺)와 비(脾)에 작용하며, 대보원기요약(大補元氣要藥)으로 항 피로 및 항 스트레스 작용, 노화방지 작용, 간 기능 촉진 및 숙취제거효과, 항방사선작용, 정력증강, 항종양작용, 그리고 alloxan 투여에 의한 고혈당에 항당뇨작용이 있는 우리 나라의 대표적인 수출생약이다.Red ginseng ( Ginseng Radix rubra ) is a dried dried bark of Panax ginseng , which acts mainly on the lungs and the nasal air. Anti-aging, liver function and hangover elimination effect, anti-radiation effect, energetic enhancement, anti-tumor effect, and anti-diabetic effect of hyperglycemia by alloxan administration.

가시오가피나무(A.senticosus)는 인삼과 같은 오가과 (Araliaceae)의 식물로, 오가피나무속 식물의 근피와 수피를 五加皮(Acanthopanacis cortex)라 하여 주로 간(肝)과 신(腎)에 작용하는 생약으로, 면역기능 및 생체 저항력 강화작용, 정력증강과 학습력향상, 간기능 보전 및 해독작용, 구속수침 stress 위궤양 억제작용, 히스타민유리 억제작용, 항방사선작용, 심근경색 개선작용, 그리고 alloxan 투여에 의한 고혈당에 잎엑스의 saponin 분획이 혈당강하효과를 나타낸다.Gasiohgapi tree (A. Senticosus) is called to the herbal which mainly acts on the liver (肝) and the new (腎) of the plant of ohgagwa (Araliaceae), such as ginseng,五加皮the muscular fatigue and bark of Acanthopanax hawthorn plants (Acanthopanacis cortex) Increasing immune function and bio-resistance, enhancing energy and learning ability, preserving liver function and detoxification, restraint stress gastric ulcer, inhibiting histamine release, anti-radiation, improving myocardial infarction, and hyperglycemia by administration of alloxan Saponin fraction of leaf extract shows hypoglycemic effect.

또한, 동충하초(Cordyceps sinensis)는 예로부터 인삼, 녹용과 함께 귀한 3대 한방 약재로 취급되어 왔으며, 불로 장생의 비약으로 결핵, 황달 치료와 아편 중독의 해독제로 이용되어 온 생약이다.Cordyceps sinensis, along with ginseng and antler, has been treated as a precious three herbal medicines, and has been used as an antidote for tuberculosis, jaundice and opioid poisoning.

상기와 같이 홍삼, 가시오가피, 동충하초등은 그 고유의 약효가 이미 알려져 있는것이며, 항당뇨활성이 보고되었더라도, alloxan 이나 STZ 유발 고혈당에 의한 결과로서 제1형 당뇨모델에 가까운 것이었다. 그런데 본발명의 실험을 통해서 본발명의 생약제제가 대부분의 당뇨환자의 형태인 2형 당뇨병 치료에 효능이 있음을 확인되었다.As mentioned above, red ginseng, thorn stem, and Cordyceps sinensis are already known for their inherent effects, and even though antidiabetic activity has been reported, alloxan or STZ-induced hyperglycemia was close to the type 1 diabetes model. However, the experiment of the present invention confirmed that the herbal medicine of the present invention is effective in treating type 2 diabetes, which is the form of most diabetic patients.

본 발명에서 상기 선택된 약재추출물을 얻기 위하여 통상의 약재추출기를 이용하였다.In the present invention, a conventional medicinal herb extractor was used to obtain the selected medicinal herb extract.

추출용매로는 10-100 % 에타놀 또는 증류수를 선택하여 적용하였으나, 추출용매의 선택이 중요한것은 아니다. 따라서, 이하 실시예에서는 증류수 추출용매가 대표적으로 기재된다.Although 10-100% ethanol or distilled water was selected as the extraction solvent, the selection of the extraction solvent is not important. Therefore, distilled water extraction solvent is representatively described in the following examples.

약재추출공정은 선택된 모든 약재원료를 대상으로 하여 동일조건이 적용In the medicine extraction process, the same conditions apply to all selected medicine ingredients.

되며, 추출온도 30 내지 100℃ 및 추출시간 1-10시간을 적용하여 반복적 실험을 수행하였다. 여기에서 추출온도 및 추출시간의 변경은 본 발명의 기술분야에 관한 통상의 지식을 가진자에 의하여 용이하게 변경될 수 있는 실험조건이다.The experiment was repeated by applying an extraction temperature of 30 to 100 ℃ and an extraction time of 1-10 hours. Herein, the change of extraction temperature and extraction time is an experimental condition that can be easily changed by those skilled in the art.

본 발명의 추출물을 임상적인 목적으로 투여시에는 1일 1회 또는 2 내지 3회의 분리용량으로하고 숙주에게 투여될 총 일일용량은 체중 1kg 당 1 내지 50mg의 범위가 바람직하나, 특정 환자에 대한 특이 용량 수준은 사용될 특정 화합물, 체중, 연령, 성, 건강상태, 식이, 투여시간, 투여방법, 배설률, 약제혼합 및 질환의 중증도에 따라 변화될 수 있다.In the case of administering the extract of the present invention for clinical purposes, it is preferable to separate the dose once or two to three times a day and the total daily dose to be administered to the host is in the range of 1 to 50 mg per kg of body weight, but is specific for a specific patient. Dosage levels may vary depending on the specific compound to be used, weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, drug mixture and severity of the disease.

본 발명의 화합물은 목적하는바에 따라 주사제 또는 경구용 제제로 투여할 수 있다.The compounds of the present invention can be administered as injections or oral formulations as desired.

주사용 제제, 예를들면 멸균 주사용 수성 또는 유성 현탁액은 공지된 기술에 따라 적합한 분산제, 습윤제 또는 현탁제를 사용하여 제조할 수 있다. 이때, 사용될 수 있는 용매에는 물, 링거액 및 생리식염액이 있으며, 멸균 고정 오일은 통상적으로 용매 또는 현탁 매질로서 사용한다. 모노-, 디-글리세라이드를 포함하여 어떠한 무자극성 고정오일도 이러한 목적으로 사용될 수 있으며, 올레산과 같은 지방산도 주사용 제제에 사용할 수 있다.Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, can be prepared using suitable dispersing agents, wetting agents or suspending agents according to known techniques. At this time, solvents that may be used include water, Ringer's solution and physiological saline solution, and sterile fixed oils are commonly used as a solvent or suspending medium. Any non-irritating fixed oil may be used for this purpose, including mono- and diglycerides, and fatty acids such as oleic acid may also be used in the preparation of injectables.

경구투여용 투여 형태는 캅셀제, 정제, 환제, 산제, 과립제 및 액제가 가능하고, 특히 캅셀제와 정제, 액제가 유용하다. 정제 및 환제는 장피제로 제조하는 것이 바람직하다. 고체 및 액체투여 형태는 본 발명에 따른 생약추출물을 슈크로오즈, 락토오즈, 전분 등과 같은 하나 이상의 불활성 희석제, 마그네슘스테아레이트, 탈크와 같은 윤활제, 칼슘 씨엠씨와 같은 붕해보조제, 결합제, 방향제, 소듐벤조에이트와 같은 방부제, 설탕 또는 과당과 같은 감미제 및 계면활성제 중에서 선택된 담체와 혼합하여 제조한다. 좀더 구체적으로 설명하면, 활성성분 이외에 부형제로서 전분과 유당을 7:3의 비율로 넣고 유동성 증대를 위하여 마그네슘 스테아레이트와 탈크를 3% 이내로 가하여 충진시킴으로써 캅셀제를 제조할 수 있고; 부형제로서 전분과 유당을 7:3의 비율로 넣고 결합제, 그리고 붕해보조제로 칼슘 씨엠씨를 가하여 타정함으로써 정제를 제조할 수 있으며; 방향제로 과일향, 방부제로 소듐벤조에이트, 감미제로 설탕 또는 과당 및 계면활성제를 첨가하여 액제를 제조할 수 있다.Dosage forms for oral administration may be capsules, tablets, pills, powders, granules, and solutions. Particularly, capsules, tablets, and solutions are useful. Tablets and pills are preferably prepared with enteric agents. Solid and liquid dosage forms can be used to prepare the herbal extracts according to the present invention with one or more inert diluents such as sucrose, lactose, starch, etc. It is prepared by mixing with a carrier selected from preservatives such as ate, sweeteners such as sugar or fructose and surfactants. More specifically, a capsule may be prepared by adding starch and lactose as an excipient in addition to the active ingredient in a ratio of 7: 3 and adding magnesium stearate and talc to within 3% to increase fluidity; Tablets can be prepared by adding starch and lactose as an excipient in a ratio of 7: 3 and adding calcium binder with a binder and a disintegration aid and tableting; A liquid preparation can be prepared by adding fruit flavor as a fragrance, sodium benzoate as a preservative, sugar or fructose as a sweetener and a surfactant.

본 발명은 선택된 약재를 추출하는 추출공정에서의 실험조건을 변경가능할 수 있으며, 상기 일반적인 제조공정조건은 본 발명의 약재추출물 선택에 부여된 발명에 영향을 미치지 아니한다.The present invention may change the experimental conditions in the extraction process of extracting the selected medicinal herbs, the general manufacturing process conditions do not affect the invention given to the selection of the medicinal extracts of the present invention.

따라서, 이하 실시예에서 명시된 추출공정 및 최종 생약제제 제조공정에서의 실시조건은 대표적인 수치만을 기재하는 것이며 이러한 수치 특정 및 한정은 본 발명인 조성물에 영향을 주지 아니한다.Therefore, the operating conditions in the extraction process and final herbal preparation manufacturing process specified in the following examples are only representative of the numerical values, and such numerical specification and limitation do not affect the composition of the present invention.

실시예Example

실시예 1Example 1

① 제1단계① First step

홍삼추출물의 제조Preparation of Red Ginseng Extract

홍삼을 증류수로 100℃에서 2시간 씩 2회 반복 추출하여, 감압농축하고 동결건조하여 홍삼추출물을 얻었다.Red ginseng was repeatedly extracted twice with distilled water at 100 ° C. for 2 hours, concentrated under reduced pressure and lyophilized to obtain red ginseng extract.

② 제2단계② Second step

가시오가피추출물의 제조Preparation of Prickly Pear Extract

가시오가피 줄기를 증류수 100℃에서 2시간 씩 2회 반복 추출하여, 감압농축하고 동결건조하여 가시오가피추출물을 얻었다.Prickly stems were repeatedly extracted twice at 100 ° C. for 2 hours, concentrated under reduced pressure and lyophilized to obtain thorny stem extracts.

③ 제3단계③ Third step

동충하초추출물의 제조Preparation of Cordyceps Sinensis Extract

동충하초를 증류수 100℃에서 2시간 씩 2회 반복 추출하여, 감압농축하고 동결건조하여 동충하초추출물을 얻었다.Cordyceps sinensis was repeatedly extracted twice at 100 ° C. for 2 hours, concentrated under reduced pressure, and lyophilized to obtain a cordyceps extract.

④ 제4단계④ 4th step

생약 멀티-비타민 혼합제제의 제조Preparation of herbal multi-vitamin blends

제1단계에서 얻은 홍삼추출물 20∼80 중량%와 제2단계에서 얻은 가시오가피추출물 80∼20 중량% 그리고 제3단계에서 얻은 동충하초 1∼5 중량%를 혼합하고 일정양[Vitamin (B10.046 중량%, B20.046 중량%, B60.046 중량%, B120.002 중량%, C 2.3 중량%, E 0.46 중량%)의 멀티-비타민을 추가혼합하였다.20 to 80% by weight of the red ginseng extract obtained in the first step, 80 to 20% by weight of the bark extract extracted in the second step, and 1 to 5% by weight of the Cordyceps sinensis obtained in the third step, were mixed [Vitamin (B 1 0.046% by weight) , B 2 0.046 wt%, B 6 0.046 wt%, B 12 0.002 wt%, C 2.3 wt%, E 0.46 wt%) multi-vitamin.

상기 제4단계에서의 혼합비율은 홍삼추출물 69.4 중량%와 가시오가피추출물 23.1 중량%와 동충하초 4∼6 중량%일 수 있다.In the fourth step, the mixing ratio may be 69.4% by weight of red ginseng extract, 23.1% by weight of thorny oocyte extract, and 4-6% by weight of Cordyceps sinensis.

상기 실시예에서 선택된 가시오가피 줄기를 대신하여 잎 또는 뿌리를 선택하여 적용할 수 있다.In the above embodiment can be applied to select the leaves or roots in place of the selected stems.

본 발명은 가시오가피추출물이 가시오가피 어느 부분에서 채취된 것인가는 본 발명의 효과를 좌우하는 중요인자가 될 수 없는 것이다. 따라서, 이하 가시오가피 추출물이라 함은 가시오가피의 잎, 줄기 또는 뿌리에서의 추출물을 언급하는 것이며, 이는 가시오가피 추출물과 관련된 반복적인 실험으로부터 확인된 사실에 기초한 것이다.In the present invention, which part of the prickly pear extract is collected is not an important factor that determines the effect of the present invention. Thus, thorny thorns extract refers to extracts on the leaves, stems or roots of thorny thorns, based on the facts identified from repeated experiments involving thorny thorns.

본 발명은 상기 실시예를 통하여 명시한 바와 같이 항2형 당뇨효과를 얻기 위하여 홍삼 추출물 및 가시오가피수피로 대표되는 가시오가피 추출물 또는 동충하초 추출물을 여러 방법으로 제조할 수 있다. 그러나, 상기 제시한 추출 방법은 각각의 생약의 혼합후 용매추출에 국한되지 아니한다.The present invention can be prepared by a number of methods to extract the extract of the thorny scabies or Cordyceps sinensis, which are represented by the red ginseng extract and thorny bark bark in order to obtain the anti-type 2 diabetes effect as described in the above examples. However, the extraction method presented above is not limited to solvent extraction after mixing each herbal medicine.

또한, 최종추출물의 존재상태는 액상 또는 분말의 어떠한 형태일 수도 있다.In addition, the presence state of the final extract may be in any form of liquid or powder.

본 발명의 분명한 효과인 2형 당뇨로 인한 고혈당 저하를 위한 선택된 약재 및 이들의 조성비율은 홍삼 추출물 20∼80 중량%, 가시오가피 추출물 80∼20 중량%Selected medicinal herbs and their composition ratio for hyperglycemic lowering due to type 2 diabetes, which is an obvious effect of the present invention, 20 to 80% by weight of red ginseng extract, 80 to 20% by weight of prickly pear extract

, 동충하초 추출물 1∼5 중량% 이며, 가장 바람직하게는 홍삼 추출물 60∼70 중량%, Cordyceps sinensis extract 1 to 5% by weight, most preferably red ginseng extract 60 to 70% by weight

, 가시오가피 추출물 20∼30 중량%, 동충하초 추출물 1∼5 중량%이다., 20-30% by weight of thorny thorns extract, 1-5% by weight of Cordyceps sinensis extract.

실험예 1Experimental Example 1

2형 당뇨 실험Type 2 diabetes experiment

제2형 당뇨 질환모델로서 KKAY마우스에 대하여 홍삼, 가시오가피, 동충하초 단독 및 혼합추출물 또한, 멀티-비타민 혼합추출물을 경구투여하기전과 1달간 경구투여후의 공복시 혈당(fasting blood glucose)을 비교검토한 후 (2000. 8. 30 경구투여후 2000. 9. 26일 혈당량 측정) 혈당상승에 대한 시료용액의 억제작용은 하기 수학식 1에 따라 대조군의 경구투여전과 경구투여후의 혈당량 차에 대한 각 시료군의 비로부터 각 시료군의 억제율을 구하여 평가하였다.As a type 2 diabetes model, KKA Y mice were compared with fasting blood glucose before and after oral administration of red ginseng, spiny ginseng, Cordyceps sinensis and mixed extracts, or multi-vitamin mixed extracts. (Measurement of blood glucose level after oral administration on August 30, 2000) The inhibitory effect of the sample solution on the blood glucose increase was determined in each sample group for the difference in blood glucose levels before oral administration and after oral administration of the control group according to Equation 1 below. The inhibition rate of each sample group was calculated | required from ratio, and it evaluated.

결과는 표 1.과 같다.The results are shown in Table 1.

표 1. 14시간 공복후의 혈당량 및 혈당상승 억제율Table 1. Glucose and Glucose Inhibition Rate after 14-Hour Fasting

구분division 대조군Control AA BB CC DD EE RosiglitazoneRosiglitazone 측정일Measurement date 혈당량(㎎/㎗)Blood glucose level (mg / dl) 90.0±6.090.0 ± 6.0 88.0±15.988.0 ± 15.9 78.6±6.378.6 ± 6.3 94.6±20.494.6 ± 20.4 108.5±9.7108.5 ± 9.7 105.3±7.5105.3 ± 7.5 86.5±7.086.5 ± 7.0 8월 30일August 30 122.0±28.0122.0 ± 28.0 119.3±22.9119.3 ± 22.9 94.5±3.194.5 ± 3.1 105.0±23.3105.0 ± 23.3 117.0±25.5117.0 ± 25.5 113.1±10.2113.1 ± 10.2 92.7±10.092.7 ± 10.0 9월 26일September 26 혈당상승억제율(%)Blood sugar suppression rate (%) -- 2.22.2 50.3* 50.3 * 67.567.5 73.5* 73.5 * 75.6* 75.6 * 80.6* 80.6 * --

A : 홍삼 (300 ㎎/㎏)A: red ginseng (300 mg / kg)

B : 가시오가피 (300 ㎎/㎏)B: visiogapi (300 mg / kg)

C : 동충하초 (300 ㎎/㎏)C: Cordyceps sinensis (300 mg / kg)

D : 홍삼 (300 ㎎/㎏) + 가시오가피 (100 ㎎/㎏) + 동충하초 (20 ㎎/㎏)D: Red ginseng (300 mg / kg) + thorn ogapi (100 mg / kg) + Cordyceps sinensis (20 mg / kg)

E : 홍삼 (300 ㎎/㎏) + 가시오가피 (100 ㎎/㎏) + 동충하초 (20 ㎎/㎏) + Vitamin (B10.2mg/kg, B20.2mg/kg, B60.2mg/kg, B120.2㎍/kg, C 10mg/kg, E 2mg/kg)E: Red ginseng (300 mg / kg) + thorny ogapi (100 mg / kg) + Cordyceps sinensis (20 mg / kg) + Vitamin (B 1 0.2mg / kg, B 2 0.2mg / kg, B 6 0.2mg / kg, B 12 0.2 μg / kg, C 10 mg / kg, E 2 mg / kg)

상기 표 1에 기재된 수치는 6회 실험하여 얻은 평균치이고, "*"는 P < 0.05 인 것을 의미한다.The numerical value shown in Table 1 above is an average value obtained by six experiments, and " * " means that P <0.05.

표 1.에서 보는 바와같이, 홍삼, 가시오가피, 동충하초의 각 추출물과 각 추출물 혼합엑스 및 각 추출물 혼합엑스와 Vitamine 혼합엑스를 대상으로 2형 당뇨모델인 KKAY고혈당 흰쥐에 대하여 1달간의 경구투여 결과 공복시 혈당이 홍삼, 가시오가피, 동충하초의 단독 추출물 중에서는 가시오가피 추출물만 50.3 %의 유의성 있는 혈당상승 억제효과를 나타내었으나, 홍삼, 가시오가피, 동충하초의 추출물 혼합엑스와 Vitamine 혼합엑스가 75.6 %와 73.5 %의 보다 강한 혈당상승 억제율을 나타내었다. 이와 같은 결과는 홍삼, 가시오가피, 동충하초와 Vitamine을 혼합하므로 서 단독투여의 경우와 달리 병용상승효과를 나타내는 것이 확인되었다. 한편 양성대조약물인 Rosiglitazone도 80.6 %의 강한 혈당상승 억제효과를 나타내었다.As shown in Table 1. Results of 1 month oral administration of KKA Y hyperglycemic rats, type 2 diabetes model, for each extract, extract extract and extract extract of red ginseng, prickly pear, Cordyceps sinensis Fasting blood glucose showed a significant inhibitory effect of 50.3% of the extracts of red ginseng, barberry, and Cordyceps sinensis, but the extracts of red ginseng, barberry, and Cordyceps were higher than 75.6% and 73.5%. It showed strong blood sugar rise inhibition rate. These results were confirmed to show a synergistic effect, unlike the case of single administration by mixing red ginseng, prickly pear, cordyceps and Vitamine. Rosiglitazone, a positive control drug, also showed a strong inhibitory effect on blood glucose elevation of 80.6%.

Claims (4)

홍삼, 가시오가피, 동충하초 추출물로 이루어진, 2형 당뇨에 효능이 있는 생약제제.Herbal medicine that is effective in type 2 diabetes, consisting of red ginseng, prickly pear, Cordyceps sinensis extract. 제1항에 있어서, 홍삼추출물 20∼80 중량%와 가시오가피추출물 80∼20 중량%그리고 동충하초 1∼5 중량%로 이루어진, 2형 당뇨에 효능이 있는 생약제제.According to claim 1, 20 to 80% by weight of red ginseng extract, 80 to 20% by weight of prickly pear extract, and 1 to 5% by weight of Cordyceps sinensis, a herbal preparation effective for type 2 diabetes. 제1항에 있어서, 멀티-비타민이 혼합된, 2형 당뇨에 효능이 있는 생약 제제.The herbal formulation according to claim 1, which is effective for type 2 diabetes, mixed with multi-vitamins. 제3항에 있어서, 상기 홍삼추출물 69.4 중량%, 상기 가시오가피추출물 23.1 중량%, 상기 동충하초 4.6 중량% 및 멀티-비타민[Vitamin (B10.046 중량%, B20.046 중량%, B60.046 중량%, B120.002 중량%, C 2.3 중량%, E 0.46 중량%〕으로 이루어진, 2형 당뇨에 효능이 있는 생약제제.According to claim 3, 69.4% by weight of the red ginseng extract, 23.1% by weight of the bark extract, 4.6% by weight of Cordyceps sinensis and multi-vitamin [Vitamin (B 1 0.046% by weight, B 2 0.046% by weight, B 6 0.046% by weight, B 12 0.002% by weight, C 2.3% by weight, consisting of 0.46% by weight] E, herbal drugs which are effective in type 2 diabetes.
KR10-2000-0062697A 2000-10-24 2000-10-24 crude drug for 2type diabetes KR100376030B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2000-0062697A KR100376030B1 (en) 2000-10-24 2000-10-24 crude drug for 2type diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2000-0062697A KR100376030B1 (en) 2000-10-24 2000-10-24 crude drug for 2type diabetes

Publications (2)

Publication Number Publication Date
KR20020031911A true KR20020031911A (en) 2002-05-03
KR100376030B1 KR100376030B1 (en) 2003-03-15

Family

ID=19695195

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0062697A KR100376030B1 (en) 2000-10-24 2000-10-24 crude drug for 2type diabetes

Country Status (1)

Country Link
KR (1) KR100376030B1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030089864A (en) * 2002-05-20 2003-11-28 이재수 Tonic
KR100523443B1 (en) * 2002-08-19 2005-10-25 주식회사 엠디바이오알파 Active extracts from natural plants showing anti-obesity and anti-diabetes
KR100685472B1 (en) * 2004-04-20 2007-02-23 주식회사 유유 Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome
KR100697184B1 (en) * 2006-01-06 2007-03-21 주식회사 농협고려인삼 A functional food for a ginseng and mulberry and banaba and the producing method therof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101275375B1 (en) * 2011-06-16 2013-06-17 동아대학교 산학협력단 Manufacturing Method of Cordyceps militaris Extracts And Health Assistance Food Comprising the Extracts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06237735A (en) * 1993-02-15 1994-08-30 Nitto Denko Corp Food having hypoglycemic action
US5560967A (en) * 1994-07-25 1996-10-01 The Excello Specialty Company Sound absorbing automotive water deflector
KR100195886B1 (en) * 1996-11-01 1999-06-15 김상조 Pharmaceutical composition for treating diabetes mellitus
JPH10245341A (en) * 1997-03-04 1998-09-14 Meiji Milk Prod Co Ltd Hypoglycemic composition
KR20010100733A (en) * 2000-05-06 2001-11-14 박태웅 Manufacturing method of red ginseng cordyceps
KR101243718B1 (en) * 2011-03-18 2013-03-13 (주)엔탑스 drainage pumping apparatus

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030089864A (en) * 2002-05-20 2003-11-28 이재수 Tonic
KR100523443B1 (en) * 2002-08-19 2005-10-25 주식회사 엠디바이오알파 Active extracts from natural plants showing anti-obesity and anti-diabetes
KR100685472B1 (en) * 2004-04-20 2007-02-23 주식회사 유유 Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome
KR100697184B1 (en) * 2006-01-06 2007-03-21 주식회사 농협고려인삼 A functional food for a ginseng and mulberry and banaba and the producing method therof

Also Published As

Publication number Publication date
KR100376030B1 (en) 2003-03-15

Similar Documents

Publication Publication Date Title
Verma et al. Diabetes mellitus treatment using herbal drugs
Nyunaï et al. Hypoglycaemic and antihyperglycaemic activity of Ageratum conyzoides L. in rats.
KR101090319B1 (en) A composition having an effect of curing and preventing diabetes mellitus
EP1013278B1 (en) The extract of pine needle and the use thereof
CN108186877A (en) For the Chinese medicine composition of syndrome of blood stasis due to qi deficiency myocardial infarction secondary prevention
KR100831621B1 (en) The plant extracts composition for the blood glucose reducing action
Njike et al. Hypoglycaemic activity of the leaves extracts of Bersama engleriana in rats.
Munyangi et al. Five case reports on treatment of diabetes by Artemisia annua and Artemisia afra herbal tea
KR101094157B1 (en) The health food for improvement of glucosuria using madisin-materials of plants
KR100376030B1 (en) crude drug for 2type diabetes
CN106798854B (en) Phyllanthus emblica leaf and preparation method thereof
KR20090126469A (en) The herb extract composition for the blood glucose reducing action
KR20230019510A (en) Red Ginseng Bokryeong Containing Aronia 6.0 BRIX Effective for Diabetes
Thallaj et al. Studying the efficacy of the plant extract of Tetracera scandens as an antidiabetic treatment
Kamala et al. Anti–Hyperglycemic and Anti–Hyperlipidemic Potentials of Psidium guajava Fruit Extract–a Review
RU2114628C1 (en) Component composition &#34;adaptovit&#34; showing antihypoxic effect
CN108186799A (en) Ground bone slender acanthopanax dissipates and preparation method
Konsue et al. Effect of Thai folklore recipe from Abutilon indicum and Mimosa pudica in streptozotocin-induced diabetic rats
KR100697632B1 (en) Pharmaceutical compositions and functional food comprising Extract of Mixture of Crude Medicine
KR20040036992A (en) Extracting method of extract from Protaetia brevitarsis grub and pharmaceutical composition for diabetes treatment containing the extract
RU2805492C1 (en) Method for correction of post-prandial glycemia
Nwoke et al. Comparative antihyperglycemic potentials of different fractions of Detarium senegalense stem bark extract on streptozotocin-induced diabetic Wistar rats
RU2805492C9 (en) Method for correction of post-prandial glycemia
KR20030059952A (en) Composition containing an extract of truncated sopungsungi-won crude drug complex for preventing and treating diabetes
CN106344780A (en) Traditional Chinese medicinal composition having blood glucose reducing effect

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100302

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee